Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds.

Multitargeting compounds comprising activity on more than a single biological target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome. Polypharmacological drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin. While their identification has long been the result of serendipity, medicinal chemistry now tends to design polypharmacology. Modern in vitro pharmacological methods and chemical probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallography, or fragment-based design equip multitarget compound development with valuable tools. In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacology. We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacology holds enormous potential to secure future therapeutic innovation.

[1]  István A. Kovács,et al.  How to design multi-target drugs , 2007, Expert opinion on drug discovery.

[2]  Laura M. Geffert,et al.  SKI-178: A multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models , 2017, Cancer translational medicine.

[3]  Jacob de Vlieg,et al.  Comparative Analysis of Pharmacophore Screening Tools , 2012, J. Chem. Inf. Model..

[4]  Anne W. Schmidt,et al.  1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents. , 1991, Journal of medicinal chemistry.

[5]  Robert J Kavlock,et al.  Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms , 2014, Nature Biotechnology.

[6]  Michael J. Keiser,et al.  Leveraging Large-scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology. , 2016, ACS chemical biology.

[7]  Holger Stark,et al.  Development of a new class of nonimidazole histamine H(3) receptor ligands with combined inhibitory histamine N-methyltransferase activity. , 2002, Journal of medicinal chemistry.

[8]  Lazaros Mavridis,et al.  Predicting targets of compounds against neurological diseases using cheminformatic methodology , 2015, Journal of Computer-Aided Molecular Design.

[9]  Chuda Chittasupho Multivalent ligand: design principle for targeted therapeutic delivery approach. , 2012, Therapeutic delivery.

[10]  Wei Li,et al.  Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles , 2017, Artif. Intell. Medicine.

[11]  Krister Wennerberg,et al.  Methods for High-Throughput Drug Combination Screening and Synergy Scoring , 2016, bioRxiv.

[12]  Yanli Wang,et al.  PubChem BioAssay: 2017 update , 2016, Nucleic Acids Res..

[13]  Jin-jian Lu,et al.  Multi-Target Drugs: The Trend of Drug Research and Development , 2012, PloS one.

[14]  Sheng-Yong Yang,et al.  Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.

[15]  D. Sejer Pedersen,et al.  Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry. , 2017, Journal of medicinal chemistry.

[16]  U. Kintscher,et al.  Characterization of New PPARγ Agonists: Analysis of Telmisartan’s Structural Components , 2009, ChemMedChem.

[17]  S. Shaw,et al.  Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats , 2012, Experimental biology and medicine.

[18]  T. Efferth,et al.  Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. , 2016, Pharmacological research.

[19]  Alimuddin Zumla,et al.  Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis , 2016, BMC Medicine.

[20]  H. Brückmann,et al.  Polypharmacology of dopamine receptor ligands , 2016, Progress in Neurobiology.

[21]  C. Cava,et al.  In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition , 2018, Journal of Translational Medicine.

[22]  J. Ohren,et al.  Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ. , 2011, Journal of medicinal chemistry.

[23]  Robert J Gillies,et al.  Hitting multiple targets with multimeric ligands , 2004, Expert opinion on therapeutic targets.

[24]  George Karypis,et al.  Target Fishing for Chemical Compounds Using Target-Ligand Activity Data and Ranking Based Methods , 2009, J. Chem. Inf. Model..

[25]  Andreas Bender,et al.  DeepSynergy: predicting anti-cancer drug synergy with Deep Learning , 2017, Bioinform..

[26]  Oliver Koch,et al.  A novel interaction fingerprint derived from per atom score contributions: exhaustive evaluation of interaction fingerprint performance in docking based virtual screening , 2018, Journal of Cheminformatics.

[27]  E. Wong,et al.  The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action. , 2010, Pharmacology & therapeutics.

[28]  Gisbert Schneider,et al.  De Novo Design of Bioactive Small Molecules by Artificial Intelligence , 2018, Molecular informatics.

[29]  M. Murcko,et al.  Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. , 2008, Journal of medicinal chemistry.

[30]  Om Silakari,et al.  Multifunctional compounds: smart molecules for multifactorial diseases. , 2014, European journal of medicinal chemistry.

[31]  A. Simeonov,et al.  Drug discovery and development for rare genetic disorders , 2017, American journal of medical genetics. Part A.

[32]  B. Cravatt,et al.  Synergy between Enzyme Inhibitors of Fatty Acid Amide Hydrolase and Cyclooxygenase in Visceral Nociception , 2009, Journal of Pharmacology and Experimental Therapeutics.

[33]  Maria Laura Bolognesi,et al.  Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer’s disease , 2011, Neurotherapeutics.

[34]  Judith M. Rollinger,et al.  Accessing target information by virtual parallel screening—The impact on natural product research , 2009 .

[35]  C. Saxena Identification of protein binding partners of small molecules using label-free methods , 2016, Expert opinion on drug discovery.

[36]  D. Steinhilber,et al.  Inhibitors of the arachidonic acid cascade: interfering with multiple pathways. , 2014, Basic & clinical pharmacology & toxicology.

[37]  Andreas Bender,et al.  Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure. , 2017, Journal of medicinal chemistry.

[38]  J. Peters Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.

[39]  Huey Eng Chua,et al.  Synergistic target combination prediction from curated signaling networks: Machine learning meets systems biology and pharmacology. , 2017, Methods.

[40]  R. Ramsay,et al.  Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration , 2016, Front. Neurosci..

[41]  Olivier Elemento,et al.  A Computational Approach for Identifying Synergistic Drug Combinations , 2017, PLoS Comput. Biol..

[42]  A. Connor,et al.  ADME and Safety Aspects of Non-cleavable Linkers in Drug Discovery and Development. , 2018, Current Topics in Medicinal Chemistry.

[43]  G. Drewes,et al.  Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry , 2015, Nature Protocols.

[44]  D. Lauro,et al.  Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD , 2018, Current opinion in pharmacology.

[45]  Thierry Langer,et al.  Molecule-pharmacophore superpositioning and pattern matching in computational drug design. , 2008, Drug discovery today.

[46]  B. Potter,et al.  Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity. , 2011, ACS medicinal chemistry letters.

[47]  Shenghua Shi,et al.  Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent , 2009, Proceedings of the National Academy of Sciences.

[48]  Norbert Handler,et al.  Pharmacophore Generation for Multiple Ligands , 2017 .

[49]  Gilles Marcou,et al.  Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores , 2008, J. Chem. Inf. Model..

[50]  S. Salomone,et al.  New drugs in psychiatry: focus on new pharmacological targets , 2017, F1000Research.

[51]  I. Amelio,et al.  Polypharmacology of Approved Anticancer Drugs. , 2017, Current drug targets.

[52]  Avner Schlessinger,et al.  A Whole Animal Platform to Advance A Clinical Kinase Inhibitor Into New Disease Space , 2017, Nature chemical biology.

[53]  Liao Jie-Lou Jeffrey and Andrews C. Robert,et al.  Targeting protein multiple conformations: a structure-based strategy for kinase drug design. , 2007 .

[54]  K. Shokat,et al.  Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.

[55]  M. Frigerio,et al.  The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates. , 2018, Current topics in medicinal chemistry.

[56]  J. Bajorath,et al.  Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.

[57]  Rona R. Ramsay,et al.  One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug , 2016, Front. Neurosci..

[58]  Maurizio Recanatini,et al.  Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.

[59]  A. Ganesan,et al.  Epigenetic polypharmacology: from combination therapy to multitargeted drugs , 2016, Clinical Epigenetics.

[60]  Paola Bisignano,et al.  Development and Application of a Virtual Screening Protocol for the Identification of Multitarget Fragments , 2016, ChemMedChem.

[61]  Andreas Evers,et al.  MARS: Computing Three-Dimensional Alignments for Multiple Ligands Using Pairwise Similarities , 2012, J. Chem. Inf. Model..

[62]  B. Potter,et al.  Synthesis and Structure–Activity Relationship Studies of Derivatives of the Dual Aromatase–Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate , 2013, ChemMedChem.

[63]  Daniel Moser,et al.  Dual-target virtual screening by pharmacophore elucidation and molecular shape filtering. , 2012, ACS medicinal chemistry letters.

[64]  Yuan Sun,et al.  Designing multi-targeted agents: An emerging anticancer drug discovery paradigm. , 2017, European journal of medicinal chemistry.

[65]  L. Wodicka,et al.  Dual kinase-bromodomain inhibitors for rationally designed polypharmacology , 2014, Nature chemical biology.

[66]  P. Low,et al.  Principles in the design of ligand-targeted cancer therapeutics and imaging agents , 2015, Nature Reviews Drug Discovery.

[67]  Z. An,et al.  Antibody-drug conjugates: recent advances in conjugation and linker chemistries , 2016, Protein & Cell.

[68]  Andreas Bender,et al.  Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases , 2017, Journal of Cheminformatics.

[69]  O. Melnyk,et al.  Assembly/disassembly of drug conjugates using imide ligation. , 2010, Organic letters.

[70]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[71]  Lu Huang,et al.  Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway , 2017, Scientific Reports.

[72]  N. M. Raghavendra,et al.  Dual or multi-targeting inhibitors: The next generation anticancer agents. , 2018, European journal of medicinal chemistry.

[73]  Erwan Bezard,et al.  Modeling Parkinson's disease in primates: The MPTP model. , 2012, Cold Spring Harbor perspectives in medicine.

[74]  L. Altucci,et al.  Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer. , 2010, Epigenomics.

[75]  C. Walsh,et al.  Prospects for new antibiotics: a molecule-centered perspective , 2013, The Journal of Antibiotics.

[76]  C. Serhan,et al.  Identification and structure elucidation of the pro‐resolving mediators provides novel leads for resolution pharmacology , 2018, British journal of pharmacology.

[77]  Mark E. B. Smith,et al.  Acid-cleavable thiomaleamic acid linker for homogeneous antibody–drug conjugation† †Electronic supplementary information (ESI) available: 1H and 13C spectra for all novel compounds, and ES-MS spectra for all reactions with proteins described herein. See DOI: 10.1039/c3cc45220d Click here for additio , 2013, Chemical communications.

[78]  P. Trail,et al.  Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. , 2002, Bioconjugate chemistry.

[79]  Krister Wennerberg,et al.  Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth. , 2015, ACS chemical biology.

[80]  Gerhard Klebe,et al.  High-Throughput Crystallography: Reliable and Efficient Identification of Fragment Hits. , 2016, Structure.

[81]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[82]  J. Pelletier,et al.  Target identification using drug affinity responsive target stability (DARTS). , 2009, Proceedings of the National Academy of Sciences of the United States of America.

[83]  Oleg A Raevsky,et al.  Applications of Multi-Target Computer-Aided Methodologies in Molecular Design of CNS Drugs. , 2019, Current medicinal chemistry.

[84]  M. Tancer,et al.  The story of antipsychotics: Past and present , 2009, Indian journal of psychiatry.

[85]  T. Wencewicz,et al.  Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii. , 2013, Journal of medicinal chemistry.

[86]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[87]  M. McCarthy,et al.  Cefiderocol: a novel siderophore cephalosporin , 2018, Expert opinion on investigational drugs.

[88]  A. Čumová,et al.  Natural compounds and combination therapy in colorectal cancer treatment. , 2018, European journal of medicinal chemistry.

[89]  G. Rosano,et al.  Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome , 2005 .

[90]  Richard S. Judson,et al.  Profiling Bioactivity of the ToxCast Chemical Library Using BioMAP Primary Human Cell Systems , 2009, Journal of biomolecular screening.

[91]  W. Ko,et al.  Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification , 2017, Experimental Neurology.

[92]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[93]  M. Scotti,et al.  Hybrid Compounds as Direct Multitarget Ligands: A Review. , 2017, Current topics in medicinal chemistry.

[94]  Jeffrey Aubé,et al.  Drug repurposing and the medicinal chemist. , 2012, ACS medicinal chemistry letters.

[95]  Ying Liu,et al.  De Novo Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy , 2014, J. Chem. Inf. Model..

[96]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[97]  Andreas Bender,et al.  From in silico target prediction to multi-target drug design: current databases, methods and applications. , 2011, Journal of proteomics.

[98]  Richard Morphy,et al.  Fragments, network biology and designing multiple ligands. , 2007, Drug discovery today.

[99]  E. Proschak,et al.  A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes , 2018, Diabetologia.

[100]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[101]  Sandra K. Wittmann,et al.  N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators. , 2016, Journal of medicinal chemistry.

[102]  Luhua Lai,et al.  Dynamic Simulations on the Arachidonic Acid Metabolic Network , 2007, PLoS Comput. Biol..

[103]  P. Senter,et al.  Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates. , 2006, Bioconjugate chemistry.

[104]  Kevan M. Shokat,et al.  Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.

[105]  Hongyu Zhao,et al.  Predicting synergistic effects between compounds through their structural similarity and effects on transcriptomes , 2016, Bioinform..

[106]  S. Sakkiah,et al.  An Innovative Strategy for Dual Inhibitor Design and Its Application in Dual Inhibition of Human Thymidylate Synthase and Dihydrofolate Reductase Enzymes , 2013, PloS one.

[107]  R. Bowser,et al.  Use of biomarkers in ALS drug development and clinical trials , 2015, Brain Research.

[108]  Markus Hartenfeller,et al.  De novo drug design. , 2010, Methods in molecular biology.

[109]  Daniel Crespy,et al.  Designing Smart Polymer Conjugates for Controlled Release of Payloads. , 2018, Chemical reviews.

[110]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[111]  Cesare R Sirtori,et al.  The pharmacology of statins. , 2014, Pharmacological research.

[112]  Matthias Goebel,et al.  Characterization of New PPARγ Agonists: Benzimidazole Derivatives – the Importance of Position 2 , 2009, ChemMedChem.

[113]  Balaguru Ravikumar,et al.  Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery , 2018, Expert opinion on drug discovery.

[114]  N. Nader,et al.  Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction , 2018, American Journal of Cardiovascular Drugs.

[115]  W. Boggess,et al.  A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic. , 2018, Journal of medicinal chemistry.

[116]  G. Drewes,et al.  Tracking cancer drugs in living cells by thermal profiling of the proteome , 2014, Science.

[117]  Petra Schneider,et al.  De Novo Design at the Edge of Chaos. , 2016, Journal of medicinal chemistry.

[118]  A. Cavalli,et al.  Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease , 2016, Molecules.

[119]  Feng Xu,et al.  Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. , 2015, Pharmacological research.

[120]  O. Engkvist,et al.  Merged Multiple Ligands , 2017 .

[121]  Yuanjia Hu,et al.  Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015 , 2017, Scientific Reports.

[122]  Keith F. Tipton,et al.  Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease , 2016, Front. Neurosci..

[123]  Jens-Uwe Peters,et al.  Polypharmacology in Drug Discovery: Peters/Polypharmacology , 2012 .

[124]  A. Petrelli,et al.  Multitarget drugs: the present and the future of cancer therapy , 2009 .

[125]  Anne W. Schmidt,et al.  3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. , 1996, Journal of medicinal chemistry.

[126]  Yi Sun,et al.  Advances in computational approaches in identifying synergistic drug combinations , 2017, Briefings Bioinform..

[127]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[128]  Markus Hartenfeller,et al.  DOGS: Reaction-Driven de novo Design of Bioactive Compounds , 2012, PLoS Comput. Biol..

[129]  T. Yap,et al.  Strategies for modern biomarker and drug development in oncology , 2014, Journal of Hematology & Oncology.

[130]  Alan Talevi,et al.  Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective , 2015, Front. Pharmacol..

[131]  M. Schubert-Zsilavecz,et al.  The Linker Approach , 2017 .

[132]  M. Schindler,et al.  Designed multiple ligands in metabolic disease research: from concept to platform. , 2013, Drug discovery today.

[133]  Jie Li,et al.  Comparative Assessment of Scoring Functions on an Updated Benchmark: 1. Compilation of the Test Set , 2014, J. Chem. Inf. Model..

[134]  M. Horowitz,et al.  New insights into the anti-diabetic actions of metformin: from the liver to the gut , 2017, Expert review of gastroenterology & hepatology.

[135]  Chris Sander,et al.  Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets , 2013, Science Signaling.

[136]  V. Francardo,et al.  Animal models of l-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse , 2018, Journal of Neural Transmission.

[137]  J. T. Jørgensen The importance of predictive biomarkers in oncology drug development , 2016, Expert review of molecular diagnostics.

[138]  Eytan Ruppin,et al.  Harnessing synthetic lethality to predict the response to cancer treatment , 2018, Nature Communications.

[139]  J. Aronson In defence of polypharmacy. , 2004, British journal of clinical pharmacology.

[140]  Antonio Lavecchia,et al.  In silico methods to address polypharmacology: current status, applications and future perspectives. , 2016, Drug discovery today.

[141]  M. Markman,et al.  From serendipity to design: the evolution of drug development in oncology. , 1997, Cleveland Clinic journal of medicine.

[142]  Luhua Lai,et al.  Dynamic eicosanoid responses upon different inhibitor and combination treatments on the arachidonic acid metabolic network. , 2012, Molecular bioSystems.

[143]  P. Nordlund,et al.  Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay , 2013, Science.

[144]  Petra Schneider,et al.  Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for ‘Orphan’ Molecules , 2013, Molecular informatics.

[145]  W. Bolosky,et al.  Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies , 2017, Proceedings of the National Academy of Sciences.

[146]  S. Fox,et al.  Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update. , 2017, ACS chemical neuroscience.

[147]  B. Potter,et al.  Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates , 2011, ChemMedChem.

[148]  Adam J. Lewis,et al.  High-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance , 2017, PLoS biology.

[149]  D. Steinhilber,et al.  Small molecules with anti-inflammatory properties in clinical development. , 2016, Pharmacology & therapeutics.

[150]  L. Silver,et al.  Multitarget ligands in antibacterial research: progress and opportunities , 2013, Expert opinion on drug discovery.

[151]  Weilin Zhang,et al.  Computational Multitarget Drug Design , 2017, J. Chem. Inf. Model..

[152]  A. Mantel‐Teeuwisse,et al.  Drug repositioning and repurposing: terminology and definitions in literature. , 2015, Drug discovery today.

[153]  Gerd Geisslinger,et al.  A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. , 2017, Journal of medicinal chemistry.

[154]  M. Papp,et al.  S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization , 2012, Journal of Pharmacology and Experimental Therapeutics.

[155]  N. Cohen,et al.  The NEWLEAD program: a new method for the design of candidate structures from pharmacophoric hypotheses. , 1993, Journal of medicinal chemistry.

[156]  Rolf Larsson,et al.  Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism , 2017, Oncotarget.

[157]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[158]  Ondřej Soukup,et al.  Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3 R Antagonism for Neurodegenerative Diseases. , 2017, Angewandte Chemie.

[159]  Dmitri B. Kireev,et al.  Structural Protein–Ligand Interaction Fingerprints (SPLIF) for Structure-Based Virtual Screening: Method and Benchmark Study , 2014, J. Chem. Inf. Model..

[160]  N. Dempster,et al.  Phenothiazinium-fluoroquinolone drug conjugates. , 2010, International journal of antimicrobial agents.

[161]  P. Ernsberger,et al.  The SHROB Model of Syndrome X: Effects of Excess Dietary Sucrose , 1999, Annals of the New York Academy of Sciences.

[162]  Richard Morphy,et al.  Designing multiple ligands - medicinal chemistry strategies and challenges. , 2009, Current pharmaceutical design.

[163]  S. Leucht,et al.  Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis , 2018, European Archives of Psychiatry and Clinical Neuroscience.

[164]  L. Polito,et al.  3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease. , 2015, ACS chemical neuroscience.

[165]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[166]  Peng Zhan,et al.  Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. , 2009, Current pharmaceutical design.

[167]  W. Geldenhuys,et al.  Rationally designed multi-targeted agents against neurodegenerative diseases. , 2013, Current medicinal chemistry.

[168]  Anthony Watts,et al.  Dynamic tuneable G protein-coupled receptor monomer-dimer populations , 2018, Nature Communications.

[169]  Michael Decker,et al.  The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats , 2016, Behavioural Brain Research SreeTestContent1.

[170]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[171]  C. Wermuth Selective optimization of side activities: another way for drug discovery. , 2004, Journal of medicinal chemistry.

[172]  J. Schwartz,et al.  Search for Histamine H3 Receptor Ligands with Combined Inhibitory Potency at Histamine N‐Methyltransferase: ω‐Piperidinoalkanamine Derivatives , 2004, Archiv der Pharmazie.

[173]  Andreas Bender,et al.  Analyzing Multitarget Activity Landscapes Using Protein-Ligand Interaction Fingerprints: Interaction Cliffs , 2015, J. Chem. Inf. Model..

[174]  B. Rolando,et al.  Designing Multitarget Anti‐inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists–COX‐2 Inhibitors , 2012, ChemMedChem.

[175]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[176]  John P. Overington,et al.  The promise and peril of chemical probes. , 2015, Nature chemical biology.

[177]  R. Albin,et al.  Serotonin, β‐amyloid, and cognition in Parkinson disease , 2018, Annals of neurology.

[178]  Sahdeo Prasad,et al.  Serendipity in Cancer Drug Discovery: Rational or Coincidence? , 2016, Trends in pharmacological sciences.

[179]  Weiwei Xue,et al.  The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective , 2016, PloS one.

[180]  Z. Kovács,et al.  Charting the chemical space around the (iso)indoline scaffold, a comprehensive approach towards multitarget directed ligands. , 2016, Bioorganic & medicinal chemistry letters.

[181]  J. Chen,et al.  Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ. , 2013, Bioorganic & medicinal chemistry letters.

[182]  D. Steinhilber,et al.  Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology. , 2018, Journal of medicinal chemistry.

[183]  V. Braun,et al.  Sideromycins: tools and antibiotics , 2009, BioMetals.

[184]  T. Long,et al.  Trihydroxamate siderophore-fluoroquinolone conjugates are selective sideromycin antibiotics that target Staphylococcus aureus. , 2013, Bioconjugate chemistry.

[185]  Hongchun Li,et al.  Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington’s Disease Model through the Application of Quantitative Systems Pharmacology , 2017, Scientific Reports.

[186]  Harren Jhoti,et al.  High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.

[187]  L Costantino,et al.  Designed multiple ligands: basic research vs clinical outcomes. , 2012, Current medicinal chemistry.

[188]  D. Grillot,et al.  Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPARγ agonists. , 2014, Bioorganic & medicinal chemistry letters.

[189]  Jordi Mestres,et al.  Polypharmacology in Precision Oncology: Current Applications and Future 
Prospects , 2016, Current pharmaceutical design.

[190]  Hugues-Olivier Bertrand,et al.  Are You Sure You Have a Good Model , 2006 .

[191]  L. Silver,et al.  Multi-targeting by monotherapeutic antibacterials , 2007, Nature Reviews Drug Discovery.

[192]  Jörn Lötsch,et al.  Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects. , 2011, Drug discovery today.

[193]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[194]  Xing Chen,et al.  NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning , 2016, PLoS Comput. Biol..

[195]  B. Admire,et al.  Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology. , 2015, Angewandte Chemie.

[196]  T. Grosser,et al.  A broad-spectrum lipidomics screen of antiinflammatory drug combinations in human blood. , 2016, JCI insight.

[197]  B. Potter,et al.  Dual aromatase-steroid sulfatase inhibitors. , 2007, Journal of medicinal chemistry.

[198]  S. Abramson,et al.  The pleiotropic functions of aspirin: mechanisms of action , 1999, Cellular and Molecular Life Sciences CMLS.

[199]  S. Fulda,et al.  Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. , 2018, European journal of medicinal chemistry.

[200]  Y. Martin,et al.  Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.

[201]  Daniel Moser,et al.  Exploring the chemical space of multitarget ligands using aligned self-organizing maps. , 2013, ACS medicinal chemistry letters.

[202]  Arthur Christopoulos,et al.  Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. , 2009, Molecular interventions.

[203]  C. Sigman,et al.  Cancer biomarkers: selecting the right drug for the right patient , 2012, Nature Reviews Drug Discovery.

[204]  Ewgenij Proschak,et al.  Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery. , 2017, Journal of medicinal chemistry.

[205]  M. Battino,et al.  The use of natural compounds for the targeting and chemoprevention of ovarian cancer. , 2017, Cancer letters.

[206]  D. Merk,et al.  Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis , 2017 .

[207]  V. Pillay,et al.  Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders. , 2016, Drug discovery today.

[208]  M. Millan,et al.  S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: I. A Mechanistic Characterization , 2012, Journal of Pharmacology and Experimental Therapeutics.

[209]  G. Drewes,et al.  Thermal proteome profiling monitors ligand interactions with cellular membrane proteins , 2015, Nature Methods.

[210]  Thierry Langer,et al.  Selective Optimization of Side Activities (SOSA): A Promising way for Drug Discovery , 2012 .

[211]  Hongma Sun,et al.  Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.

[212]  U. McDermott,et al.  High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer , 2017, Scientific Data.

[213]  M. Suckow,et al.  Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo. , 2017, Journal of medicinal chemistry.

[214]  Li Wang,et al.  Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. , 2014, European journal of medicinal chemistry.

[215]  Sean Ekins,et al.  In silico repositioning of approved drugs for rare and neglected diseases. , 2011, Drug discovery today.

[217]  Sourav Bandyopadhyay,et al.  A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance , 2018, Cell reports.

[218]  Luhua Lai,et al.  Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. , 2008, Journal of medicinal chemistry.

[219]  Cristina Tintori,et al.  Targets Looking for Drugs: A Multistep Computational Protocol for the Development of Structure-Based Pharmacophores and Their Applications for Hit Discovery , 2008, J. Chem. Inf. Model..

[220]  R. Glennon,et al.  5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. , 1986, Journal of medicinal chemistry.

[221]  Bernhard Kuster,et al.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.

[222]  Maria F. Sassano,et al.  Automated design of ligands to polypharmacological profiles , 2012, Nature.

[223]  Richard Morphy,et al.  The physicochemical challenges of designing multiple ligands. , 2006, Journal of medicinal chemistry.

[224]  Rona R. Ramsay,et al.  A perspective on multi-target drug discovery and design for complex diseases , 2018, Clinical and Translational Medicine.

[225]  G. Lip,et al.  Effects of Aspirin on Endothelial Function and Hypertension , 2016, Current Hypertension Reports.

[226]  S. Laufer,et al.  Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases. , 2017, Journal of medicinal chemistry.

[227]  D. Sall,et al.  Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. , 2012, Journal of medicinal chemistry.

[228]  Maurizio Recanatini,et al.  The role of fragment-based and computational methods in polypharmacology. , 2012, Drug discovery today.

[229]  J. Medina-Franco,et al.  Shifting from the single to the multitarget paradigm in drug discovery. , 2013, Drug discovery today.

[230]  Herbert Waldmann,et al.  Target identification for small bioactive molecules: finding the needle in the haystack. , 2013, Angewandte Chemie.

[231]  Dominik Dolles,et al.  Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles. , 2018, Journal of medicinal chemistry.